Krishna Gopal Gupta & Sons (HUF), a promoter group entity, purchased 1,016 equity shares of GKB Ophthalmics Ltd between June 8 and June 17, 2026. The transactions were executed on the BSE for an aggregate value of ₹64,801.77. The disclosure was made pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The purchases were made on the open market across five separate trading days. The Karta of the HUF, K.G. Gupta, undertook to preserve transaction details for three years and agreed to hold the acquired securities for a minimum period of six months. The entity confirmed that the transactions did not exceed the threshold limit prescribed under the regulations but were disclosed as a corporate governance measure.

Transaction Details

The following table outlines the specific acquisitions made by the promoter group entity:

The intimation regarding these transactions was submitted to the company on June 30, 2026. GKB Ophthalmics subsequently forwarded the disclosure to the Bombay Stock Exchange on the same day.

GKB Ophthalmics Limited returned to profitability in the financial year ended March 31, 2026, reporting a consolidated net profit of ₹302.72 lakh compared to a net loss of ₹707.92 lakh in the previous year. The turnaround was driven by a 36.8% increase in revenue from operations, which rose to ₹15,130.83 lakh from ₹11,031.86 lakh in FY25. The company’s Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 27, 2026.

On a standalone basis, the company reported a net loss of ₹356.79 lakh for FY26, an improvement from the net loss of ₹610.79 lakh in the previous year. Standalone revenue from operations decreased to ₹2,564.41 lakh from ₹3,274.94 lakh in FY25. The financial performance was impacted by exceptional items amounting to ₹178.99 lakh, primarily due to additional liabilities recognised for gratuity and compensated absences following the notification of new Labour Codes.

Consolidated Financial Performance

The Group’s total income for FY26 stood at ₹15,130.83 lakh, a significant increase from ₹11,031.86 lakh in the prior year. Total expenses for the year were ₹14,635.59 lakh, compared to ₹11,722.79 lakh in FY25. The profit before tax for the year was ₹310.37 lakh, a reversal from the loss before tax of ₹672.62 lakh in the previous year.

For the quarter ended March 31, 2026, the consolidated net profit was ₹111.94 lakh, while revenue from operations stood at ₹2,979.27 lakh. The company reported a basic earnings per share (EPS) of ₹2.42 for FY26, compared to a negative EPS of ₹13.98 in the previous year.

Standalone Financials and Exceptional Items

Standalone total income for FY26 was ₹3,161.22 lakh, down from ₹3,472.16 lakh in the previous year. The company reported a total comprehensive loss of ₹334.88 lakh for the year. The exceptional items of ₹178.99 lakh included ₹120.69 lakh for gratuity liability and ₹28.71 lakh for compensated absences, recognised in the quarter ended March 31, 2026.

Subsidiary and Operational Updates

The Board of Directors of GSV Ophthalmics Private Limited, a material subsidiary, had proposed voluntary winding up as it was not carrying any business. The Holding Company received the total investment of ₹11.70 crore and a residual share of equity of ₹69.72 lakh as deemed dividend by the reporting date. The audited results were subjected to a limited review by the statutory auditors, M S K A & Associates LLP.